

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Makoto YOSHIMOTO et al. **Confirmation No. 5398**  
Group Art Unit: 1632  
Appl. No. : 10/577,302 (National Stage of PCT/JP2004/016373)  
Examiner: not yet assigned  
I. A. Filed : October 28, 2004  
For : TRANSGENIC NON-HUMAN MAMMAL

**INFORMATION DISCLOSURE STATEMENT**

Commissioner for Patents  
U.S. Patent and Trademark Office  
Customer Service Window, Mail Stop Amendment  
Randolph Building  
401 Dulany Street  
Alexandria, VA 22314

Sir:

Pursuant to 37 C.F.R. § 1.56 and 37 C.F.R. §§ 1.97-1.98, Applicants hereby direct the Examiner's attention to the following documents cited in the specification and International Search Report for International Application PCT/JP2004/016373 of which the above-referenced application is the U.S. National Stage Application. Copies of the International Search Report (in English and Japanese) were enclosed with the papers when entering the National Stage on April 28, 2006:

- (1) Neurobiol. Dis., 2001, 8(3), pp.535-539;
- (2) JP 2003-199460 A; accompanied by an English language abstract provided by esp@cenet;
- (3) WO 01/60794 A2, August 15, 2002; Applicants note that this document is also discussed in the present application, beginning at page 2, line 11;

- (4) U.S. Patent Application Publication No. 2004/0128706, which is a family member of item (3);
- (5) U.S. Patent Application Publication No. 2002/0111321 (Klein et al.), August 15, 2002;
- (6) U.S. Patent Application Publication No. 2004/0205833, which is a family member of item (5);
- (7) WO 98/59050 A1, December 30, 1998, Applicants note that this document is also discussed in the present application, beginning at page 2, line 11;
- (8) J. Neurosci., 2000, 20(16), pp. 6021-6029;
- (9) Science, 2000, 287 (5456), pp. 1265-1269;
- (10) Exp. Neurol., 2002, 175(1), pp. 35-48;
- (11) Proc. Natl. Acad. Sci. USA, 2003, 100(5), pp. 2884-2889;
- (12) Proc. Natl. Acad. Sci. USA, 2002, 99(16), pp. 10813-10818;
- (13) Brain Res., 2002, 926 (1-2), pp. 42-50;
- (14) Neuroscience, 2000, 97(2), pp.279-284;
- (15) J. Biol. Chem., 2002, 277(32), pp. 28512-28520;
- (16) Biochemistry, 2002, 41(46), pp. 13782-13790;
- (17) Bulletin of the Japanese Society for Neurochemistry, 10 August 2004, 43(2,3) p. 369,0G1-06;
- (18) Neurobiol. Dis., 2004 November, 17(2), p.123-30; and
- (19) K. Kobayashi et al., Proceedings of the National Academy of Sciences USA, Vol. 89, pp. 1631-1635, cited in the specification beginning on page 19, line 3.

Applicants note that items, 1, 10, 13, 14, 16-18 were cited in the International Search Report, accordingly copies of these documents should have been forwarded by the International Bureau. Therefore, copies of these documents are not being submitted herewith. The Examiner is accordingly requested to consider each of these documents, and to make them of record in this application by initialing in the appropriate spaces on the attached Form-1449. Applicants respectfully requests that the Examiner include a copy of the initialed Form PTO-1449 with the next communication from the U.S. Patent and Trademark Office. If the Examiner needs additional copies of any of the documents, the Examiner is requested to contact the undersigned.

In accordance with 37 C.F.R. § 1.98 and the waiver thereto, a copy of the U.S. published patent application is not enclosed herewith. However, if a copy is needed, the Examiner is respectfully requested to contact the undersigned.

Copies of above listed documents (except for documents 1, 4, 5, 6, 10, 13, 14, and 16-18), the Written Opinion and International Preliminary Report on Patentability (in English) for International Application PCT/JP2004/016373 are enclosed together with a duly completed Form PTO-1449.


The Examiner is accordingly requested to consider each of these documents, and to make them of record in this application by initialing in the appropriate spaces on the Form PTO-1449. Applicants respectfully request that the Examiner include a copy of the initialed Form PTO-1449 with the next communication from the U.S. Patent and Trademark Office.

Applicants note that while this Supplemental Information Disclosure Statement is being filed more than three months from the filing date, Applicants have not received an action on the merits from the U.S. Patent and Trademark Office. Accordingly, consideration of the enclosed documents are required under 37 C.F.R. 1.97(b)(3).

However, if an action on the merits has been mailed prior to the filing date of this Supplemental Information Disclosure Statement, Applicants hereby authorize the charging of any required fees necessary for consideration of the documents cited herein to Deposit Account No. 19-0089.

Any comments or questions concerning this application can be directed to the undersigned at the telephone number given below.

Respectfully submitted,  
Makoto YOSHIMOTO et al

  
Bruce H. Bernstein  
Reg. No. 29,027 42,920

April 19, 2007  
GREENBLUM & BERNSTEIN, P.L.C.  
1950 Roland Clarke Place  
Reston, VA 20191  
(703) 716-1191


FORM PTO-1449

U.S. Department of Commerce  
Patent and Trademark OfficeAtty. Docket No.  
P29879Application No.  
10/577,302

## INFORMATION DISCLOSURE STATEMENT

BY APPLICANT

(Use several sheets if necessary)

Applicant  
Makoto YOSHIMOTO et al.Filing Date  
October 28, 2004Group  
1632

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	2004/	0 1 2 8 7 0 6	07/01/04	MASLIAN et al.			
	2002/	0 1 1 1 3 2 1	08/15/02	KLEIN et al.			
	2004/	0 2 0 5 8 3 3	10/14/04	KLEIN et al.			

## FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO
	2003	- 1 9 9 4 6 0	07/15/03	JAPAN			
	01	/ 6 0 7 9 4	08/15/02	W.I.P.O			
	98/	5 9 0 5 0	12/30/98	W.I.P.O			

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	1	Neurobiol. Dis., 2001, 8(3), pp.535-539
	2	J. Neurosci., 2000, 20(16), pp. 6021-6029.
	3	Science, 2000, 287 (5456), pp. 1265-1269.
	4	Exp. Neurol., 2002, 175(1), pp. 35-48.
	5	Proc. Natl. Acad. Sci. USA, 2003, 100(5), pp. 2884-2889.
	6	Proc. Natl. Acad. Sci. USA, 2002, 99(16), pp. 10813-10818.
	7	Brain Res., 2002, 926 (1-2), pp. 42-50.
	8	Neuroscience, 2000, 97(2), pp.279-284.
	9	J. Biol. Chem., 2002, 277(32), pp. 28512-28520
	10	Biochemistry, 2002, 41(46), pp. 13782-13790
	11	Bulletin of the Japanese Society for Neurochemistry, 10 August 2004, 43(2,3) p. 369,0G1-06.
	12	Neurobiol. Dis., 2004 November, 17(2), p.123-30.
	13	K. Kobayashi et al., Proceedings of the National Academy of Sciences USA, Vol. 89, pp. 1631-1635.
	14	English language Abstract of JP 2003-199460.

EXAMINER

DATE CONSIDERED

\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.